Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713325 | 0.92 | TSHR (0.50) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL4043953 | 0.92 | RECQL (0.64) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL1712987 | 0.88 | TSHR (0.48) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL1713264 | 0.88 | TSHR (0.53) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL1713157 | 0.86 | POLB (0.49) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL10985089 | 0.84 | ALDH1A1 (0.72) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL1684895 | 0.84 | — | — | |
| SCHEMBL574934 | 0.83 | SMN1; SMN2 (0.63) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL1713386 | 0.80 | SMN1; SMN2 (0.40) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL699214 | 0.80 | KIT (0.44) | TSHRALDH1A1POLBSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-9266835-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | claimed |
| CN-105102446-A | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS INC | 2015-11-25 | — | — | CN | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| WO-2015130444-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | WO | claimed |
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | claimed |
| CN-103396412-A | Modifier of 5-HT2A serotonin receptor | ARENA PHARM INC | 2013-11-20 | — | — | CN | claimed |
| US-5917043-A | INTERMEDIATES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | claimed |
| EP-0912574-A1 | BETA-LACTAMS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-06 | — | — | EP | claimed |
| EP-0779888-B1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-04-28 | — | — | EP | claimed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | claimed |
| WO-1997045429-A1 | BETA-LACTAMS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-12-04 | — | — | WO | claimed |
| CN-1157619-A | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1997-08-20 | — | — | CN | claimed |
| EP-0779888-A1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1997-06-25 | — | — | EP | claimed |
| CN-1150950-A | Cephalosporin derivatives | HOFFMANN LA ROCHE (CH) | 1997-06-04 | — | — | CN | claimed |
| EP-0761673-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-12 | — | — | EP | claimed |
| WO-1996007657-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1996-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | TSHR 850/4885ALDH1A1 1204/4885POLB 3741/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | TSHR 4226/4885ALDH1A1 4711/4885POLB 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.